These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 18784598

  • 21. The evolution of botulinum neurotoxin type A for cosmetic applications.
    Carruthers J, Carruthers A.
    J Cosmet Laser Ther; 2007 Sep; 9(3):186-92. PubMed ID: 17763029
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [Botulinum toxin for the treatment of pain syndromes].
    Ferreira JJ, Couto M, Costa J, Coelho M, Rosa MM, Sampaio C.
    Acta Reumatol Port; 2006 Sep; 31(1):49-62. PubMed ID: 17058384
    [Abstract] [Full Text] [Related]

  • 24. The use of botulinum toxin in physical medicine and rehabilitation.
    Cuevas-Trisán RL, Cruz-Jiménez M.
    Bol Asoc Med P R; 2006 Sep; 98(1):42-55. PubMed ID: 19610549
    [Abstract] [Full Text] [Related]

  • 25. Compositional differences among commercially available botulinum toxin type A.
    Bakshi E, Hartstein ME.
    Curr Opin Ophthalmol; 2011 Sep; 22(5):407-12. PubMed ID: 21825992
    [Abstract] [Full Text] [Related]

  • 26. Clinical differences between botulinum neurotoxin type A and B.
    Bentivoglio AR, Del Grande A, Petracca M, Ialongo T, Ricciardi L.
    Toxicon; 2015 Dec 01; 107(Pt A):77-84. PubMed ID: 26260691
    [Abstract] [Full Text] [Related]

  • 27. Overview of botulinum neurotoxins.
    Lowe NJ.
    J Cosmet Laser Ther; 2007 Dec 01; 9 Suppl 1():11-6. PubMed ID: 17885881
    [Abstract] [Full Text] [Related]

  • 28. Molecular biology of botulinum neurotoxin serotype A: a cosmetic perspective.
    Eapen BR.
    J Cosmet Dermatol; 2008 Sep 01; 7(3):221-5. PubMed ID: 18789058
    [Abstract] [Full Text] [Related]

  • 29. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review).
    Simpson DM, Gracies JM, Graham K, Hallett M, Miyasaki J, Naumann M, Russman B, Simpson L, So Y.
    Neurology; 2009 Sep 01; 73(9):736-7; author reply 737-8. PubMed ID: 19728407
    [No Abstract] [Full Text] [Related]

  • 30. Clinical utility of different botulinum neurotoxin preparations.
    Abrams SB, Hallett M.
    Toxicon; 2013 Jun 01; 67():81-6. PubMed ID: 23375537
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Embracing the Versatility of Botulinum Neurotoxins in Conventional and New Therapeutic Applications.
    Rasetti-Escargueil C, Palea S.
    Toxins (Basel); 2024 Jun 04; 16(6):. PubMed ID: 38922155
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Using translational medicine to understand clinical differences between botulinum toxin formulations.
    Aoki KR, Ranoux D, Wissel J.
    Eur J Neurol; 2006 Dec 04; 13 Suppl 4():10-9. PubMed ID: 17112345
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.